moomoo ID:0
Log Out
  • English
  • 中文繁体
  • 中文简体

MaxCyte (NASDAQ:MXCT) Versus Absci (NASDAQ:ABSI) Head-To-Head Analysis

Defense World ·  09/16 14:01

MaxCyte (NASDAQ:MXCT – Get Rating) and Absci (NASDAQ:ABSI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of recent ratings for MaxCyte and Absci, as provided by MarketBeat.

Get MaxCyte alerts:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte 0 0 1 0 3.00
Absci 2 0 5 0 2.43

MaxCyte presently has a consensus price target of $11.00, suggesting a potential upside of 85.50%. Absci has a consensus price target of $14.00, suggesting a potential upside of 250.00%. Given Absci's higher probable upside, analysts clearly believe Absci is more favorable than MaxCyte.

Volatility and Risk

MaxCyte has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Absci has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Institutional & Insider Ownership

66.4% of MaxCyte shares are owned by institutional investors. Comparatively, 45.4% of Absci shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Comparatively, 19.4% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares MaxCyte and Absci's net margins, return on equity and return on assets .

Net Margins Return on Equity Return on Assets
MaxCyte -47.92% -7.60% -6.96%
Absci -2,223.07% -29.31% -25.26%

Earnings and Valuation

This table compares MaxCyte and Absci's top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MaxCyte $33.89 million 17.82 -$19.08 million ($0.20) -29.65
Absci $4.78 million 77.69 -$100.96 million ($1.26) -3.17

MaxCyte has higher revenue and earnings than Absci. MaxCyte is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.


MaxCyte beats Absci on 9 of the 14 factors compared between the two stocks.

About MaxCyte

(Get Rating)

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

About Absci

(Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites and Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.